Esophageal cancer
Conditions
Interventions
Control group :Intravenous pumping 0.9%NS
Low-dose esketamine group:Before anesthesia induction, 0.1 mg/kg of esketamine was intravenously injected, and then it was continuously infused at a rate of 0.1 mg/kg/h until 30 minutes before the end
The medium-dose esketamine group:Before anesthesia induction, 0.25 mg/kg of esketamine was intravenously injected. Subsequently, it was continuously infused at a rate of 0.2 mg/kg/h until 30 minutes b
The high-dose esketamine group:Before anesthesia induction, 0.5 mg/kg of esketamine was intravenously injected. Subsequently, it was continuously infused at a rate of 0.5 mg/kg/h until 30 minutes befo
Sponsors
The First Affiliated Hospital of Bengbu Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 65 to 80 years; 2. Patients with esophageal cancer scheduled for single-lung ventilation anesthesia with double-lumen bronchial intubation; 3. The ASA classification is I to II; 4. Body Mass Index (BMI): 18 - 25 kg/m^2; 5. Agree to undergo postoperative patient-controlled intravenous analgesia; 6. Agree to sign the informed consent form to participate in the trial.
Exclusion criteria
Exclusion criteria: 1.Patients with dysfunction of important vital organs (heart, lungs, liver, kidneys, etc.); 2.Those who have been using analgesic drugs, narcotic sedatives and hormone drugs or immunosuppressants for a long time; 3. Those with mental disorders or who have been taking psychotropic drugs for a long time; 4. Those who have been heavy drinkers for a long time; 5. Those who are allergic to esketamine or have contraindications (such as increased intracranial pressure, intraocular pressure, severe hypertension, etc.); 6. Those who had fever or infection within 2 weeks before the operation and used non-steroidal anti-inflammatory drugs; 7. Those with immune system diseases or low immune function; 8. Those with communication disorders (severe visual or auditory impairments, etc.) or those who cannot complete NRS and QoR-15 scoring; 9. Those who have participated in other studies within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of serum HS, ET-1, TM, CC-16 and SP-D; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood gas indicators;NRS score; Ramsay sedation score;QoR-15 scores at 1 and days after surgery;Heart rate; | — |
Countries
China
Contacts
Public ContactZhang Ying
The First Affiliated Hospital of Bengbu Medical University
Outcome results
None listed